Elimination of liposomes by different separation principles used in low-density lipoprotein apheresis

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 1, 2008, Pages 2-12

  Pütz, Gerhard ^a   Eckes, Jürgen ^b   Schmah, Oliver ^a   Winkler, Karl ^a   Wieland, Heinrich ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TellTargeting ^*  (Germany)

Author keywords

Apheresis; Blood component removal; Cancer chemotherapy; Drug delivery systems; Liposomes

Indexed keywords

CALCIUM; DEXTRAN SULFATE; HEPARIN; HEPARIN SEPHAROSE; LIPOSOME; LOW DENSITY LIPOPROTEIN; SEPHAROSE; UNCLASSIFIED DRUG;

ADSORPTION CHROMATOGRAPHY; APHERESIS; ARTICLE; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL;

ADSORPTION; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; CALCIUM; CHOLESTEROL, LDL; CHROMATOGRAPHY; DRUG DELIVERY SYSTEMS; HEPARIN; HUMANS; LIPOSOMES; MEMBRANES, ARTIFICIAL; NEOPLASMS; PLASMA; PRECIPITATION;

EID: 38849159923     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2007.00535.x     Document Type: Article

References (28)

1. Allen TM, Cullis PR. Drug delivery systems: entering the Mainstream. Science 2004 303 : 1818 22.
2. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999 51 : 692 743.
3. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmakokinet 2003 42 : 419 36.
4. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000 65 : 271 84.
5. Charrois GJR, Allen TM. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 2003 306 : 1058 67.
6. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001 7 : 243 54.
7. Northfelt DW, Martin FJ, Working P et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi sarcoma. J Clin Pharmacol 1996 36 : 55 63.
8. Bosch T. Therapeutic apheresis-state of the art in the year 2005. Ther Apher Dial 2005 9 : 459 68.
9. Klingel R, Fassbender T, Fassbender C, Göhlen B. From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis. Ther Apher Dial 2003 7 : 350 85.
10. Wieland H, Seidel D. A simple specific method for precipitation of low-density lipoproteins. J Lipid Res 1983 24 : 904 9.
11. Asahi T, Yamamoto T, Kutsuki H. Blood purification therapies using dextran sulfate cellulose columns Liposorber and Selesorb. Ther Apher Dial 2003 7 : 73 7.
12. Koll RA. LDL-Therasorb immunoadsorption for the treatment of severe hypercholesterolemia refractory to conventional therapy. Ther Apher 1998 2 : 142 6.
13. Dräger LJ, Julius U, Kraenzle K et al. DALI - the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998 28 : 994 1002.
14. Otto C, Kern P, Bambauer R, Kallert S, Schwandt P, Parhofer KG. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (liposorber D) in severe hypercholesterolemia. Artif Organs 2003 27 : 1116 22.
15. Malchesky PS, Koo AP, Roberson GA, Hadsell AT, Rybicki LA. Apheresis technologies and clinical applications, The 2002 International Apheresis Registry. Ther Apher Dial 2004 8 : 124 43.
16. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped Volume and ability to maintain a membrane potential. Biochim Biophys Acta 1985 812 : 55 65.
17. Pütz G, Schmider W, Nitschke R, Kurz G, Blum HE. Synthesis of phospholipid-conjugated bile salts and interaction of bile salt-coated liposomes with cultured hepatocytes. J Lipid Res 2005 46 : 2325 38.
18. Papahadjopoulos D, Watkins JC. Phospholipid model membranes. II. Permeability properties of hydrated liquid crystals. Biochim Biophys Acta 1967 135 : 639 52.
19. Ostrowsky N. Liposome size measurements by photon correlation spectroscopy. Chem Phys Lipids 1993 64 : 45 56.
20. Stewart JCM. Colorometric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980 104 : 10 14.
21. Schubert R, Schmidt KH. Structural changes in vesicle membranes and mixed micelles of various lipid compositions after binding of different bile salts. Biochemistry 1988 27 : 8787 94.
22. Semple SC, Chonn A, Cullis PR. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv Drug Del Rev 1998 32 : 3 17.
23. Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann Rev Biophys Bioeng 1980 9 : 467 508.
24. Glaser DS, Yost TJ, Eckel RH. Preheparin lipoprotein lipolytic activities: relationship to plasma lipoproteins and postheparin lipolytic activities. J Lipid Res 1992 33 : 209 14.
25. Scherphof G, Roerdink F, Waite M, Parks J. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 1978 542 : 296 307.
26. Burstein M, Scholnick HR. Lipoprotein-Polyanion-Metal Interactions. Adv Lipid Res 1973 11 : 67 108.
27. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther 1998 5 : 930 7.
28. Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I. Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta 2005 1669 : 155 63.